Metformin versus oral contraceptive pill in polycystic ovary syndrome: a Cochrane review (Q36721550)

15 August 2017

0 references

1 reference

title

Metformin versus oral contraceptive pill in polycystic ovary syndrome: a Cochrane review (English)

1 reference

polycystic ovary syndrome

15 August 2017

1 reference

1 reference

combined oral contraceptive pill

1 reference

1 reference

Michael F Costello

1

1 reference

15 August 2017

Bhushan Shrestha

2

1 reference

15 August 2017

John Eden

3

1 reference

15 August 2017

Neil P Johnson

4

1 reference

15 August 2017

Peter Sjoblom

5

1 reference

15 August 2017

language of work or name

English

0 references

publication date

29 January 2007

1 reference

15 August 2017

1 reference

15 August 2017

22

1 reference

15 August 2017

1200-1209

1 reference

15 August 2017

5

1 reference

Insulin sensitizers for polycystic ovary syndrome

15 August 2017

1 reference

https://api.crossref.org/works/10.1093%2FHUMREP%2FDEM005

The pathophysiology of polycystic ovary syndrome: trying to understand PCOS and its endocrinology

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHUMREP%2FDEM005

What is polycystic ovary syndrome? Are national views important?

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHUMREP%2FDEM005

Dyslipidemia and the metabolic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHUMREP%2FDEM005

Should unpublished data be included in meta-analyses? Current convictions and controversies

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHUMREP%2FDEM005

A systematic review of the reproductive system effects of metformin in patients with polycystic ovary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHUMREP%2FDEM005

A modern medical quandary: polycystic ovary syndrome, insulin resistance, and oral contraceptive pills

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHUMREP%2FDEM005

Publication bias and clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHUMREP%2FDEM005

Profound peripheral insulin resistance, independent of obesity, in polycystic ovary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHUMREP%2FDEM005

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHUMREP%2FDEM005

Pharmacologic Treatment of Polycystic Ovary Syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHUMREP%2FDEM005

Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS).

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHUMREP%2FDEM005

Users' guides to the medical literature. II. How to use an article about therapy or prevention. A. Are the results of the study valid? Evidence-Based Medicine Working Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHUMREP%2FDEM005

Descriptive review of the evidence for the use of metformin in polycystic ovary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHUMREP%2FDEM005

Metformin or antiandrogen in the treatment of hirsutism in polycystic ovary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHUMREP%2FDEM005

Polycystic ovary syndrome and endometrial carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHUMREP%2FDEM005

Polycystic ovary syndrome - from gynaecological curiosity to multisystem endocrinopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHUMREP%2FDEM005

Should patients with polycystic ovarian syndrome be treated with metformin? A note of cautious optimism

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHUMREP%2FDEM005

Systematic literature review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHUMREP%2FDEM005

Insulin-sensitizing agents as primary therapy for patients with polycystic ovarian syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHUMREP%2FDEM005

Metformin versus ethinyl estradiol-cyproterone acetate in the treatment of nonobese women with polycystic ovary syndrome: a randomized study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHUMREP%2FDEM005

Strategies for the use of insulin-sensitizing drugs to treat infertility in women with polycystic ovary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHUMREP%2FDEM005

Insulin resistance, polycystic ovary syndrome, and type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHUMREP%2FDEM005

Effects of metformin and ethinyl estradiol-cyproterone acetate on lipid levels in obese and non-obese women with polycystic ovary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHUMREP%2FDEM005

Combined oral contraceptives in the treatment of polycystic ovary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHUMREP%2FDEM005

Long-term health consequences of PCOS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHUMREP%2FDEM005

21 January 2018

Identifiers

DOI

10.1093/HUMREP/DEM005

1 reference

15 August 2017

1 reference